Alzinova presents its company and projects to investors and international pharmaceutical companies
Alzinova AB (publ) ("Alzinova" or the "Company") will present the Company at both Swedish and international investor meetings during the autumn. The Company will participate in one of the major biotech conferences in Europe, BIO-Europe, which is a forum for partner meetings where the Company will present the vaccine candidate ALZ-101 and the antibody ALZ-201 to potential partners.Alzinova's strategy, to develop an effective and safe treatment for Alzheimer's disease that targets the toxic forms of amyloid beta, the oligomers, has been gaining interest. Preclinical data has documented "best